These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 37220082

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Impact of Gastric pH Variations on the Release of Amorphous Solid Dispersion Formulations Containing a Weakly Basic Drug and Enteric Polymers.
    Nguyen HT, Van Duong T, Taylor LS.
    Mol Pharm; 2023 Mar 06; 20(3):1681-1695. PubMed ID: 36730186
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Synergistic effect of polymers in stabilizing amorphous pretomanid through high drug loaded amorphous solid dispersion.
    Juneja M, Mehtre K, Saini V, Singh R, Amate P, Kashyap M, Sangamwar AT.
    Drug Deliv Transl Res; 2024 Jun 05. PubMed ID: 38837117
    [Abstract] [Full Text] [Related]

  • 5. Balancing Solid-State Stability and Dissolution Performance of Lumefantrine Amorphous Solid Dispersions: The Role of Polymer Choice and Drug-Polymer Interactions.
    Hiew TN, Zemlyanov DY, Taylor LS.
    Mol Pharm; 2022 Feb 07; 19(2):392-413. PubMed ID: 34494842
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance.
    Indulkar AS, Lou X, Zhang GGZ, Taylor LS.
    Mol Pharm; 2019 Mar 04; 16(3):1327-1339. PubMed ID: 30669846
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In Vitro and In Vivo Behaviors of KinetiSol and Spray-Dried Amorphous Solid Dispersions of a Weakly Basic Drug and Ionic Polymer†.
    Jermain SV, Lowinger MB, Ellenberger DJ, Miller DA, Su Y, Williams RO.
    Mol Pharm; 2020 Aug 03; 17(8):2789-2808. PubMed ID: 32520562
    [Abstract] [Full Text] [Related]

  • 12. Elucidating the effect of crystallization on drug release from amorphous solid dispersions in soluble and insoluble carriers.
    Ojo AT, Ma C, Lee PI.
    Int J Pharm; 2020 Dec 15; 591():120005. PubMed ID: 33132149
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Interplay of Drug-Polymer Interactions and Release Performance for HPMCAS-Based Amorphous Solid Dispersions.
    Bapat P, Paul S, Tseng YC, Taylor LS.
    Mol Pharm; 2024 Mar 04; 21(3):1466-1478. PubMed ID: 38346390
    [Abstract] [Full Text] [Related]

  • 15. Amorphous solid dispersion of nisoldipine by solvent evaporation technique: preparation, characterization, in vitro, in vivo evaluation, and scale up feasibility study.
    Chavan RB, Lodagekar A, Yadav B, Shastri NR.
    Drug Deliv Transl Res; 2020 Aug 04; 10(4):903-918. PubMed ID: 32378174
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Characterization of Phase Transformations for Amorphous Solid Dispersions of a Weakly Basic Drug upon Dissolution in Biorelevant Media.
    Elkhabaz A, Sarkar S, Simpson GJ, Taylor LS.
    Pharm Res; 2019 Oct 30; 36(12):174. PubMed ID: 31667638
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. pH-Dependent supersaturation from amorphous solid dispersions of weakly basic drugs.
    Wang B, Nethercott MJ, Narula A, Hanrahan M, Kuang S, Wenslow RM, Li N.
    Pharm Res; 2022 Nov 30; 39(11):2919-2936. PubMed ID: 34890018
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.